Premium
Response to azolic antifungal agents for treating feline sporotrichosis
Author(s) -
Pereira S. A.,
Passos S. R. L.,
Silva J. N.,
Gremião I. D. F.,
Figueiredo F. B.,
Teixeira J. L.,
Monteiro P. C. F.,
Schubach T. M. P.
Publication year - 2010
Publication title -
veterinary record
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 99
eISSN - 2042-7670
pISSN - 0042-4900
DOI - 10.1136/vr.166.10.290
Subject(s) - ketoconazole , itraconazole , sporotrichosis , cats , medicine , antifungal , adverse effect , veterinary medicine , dermatology
The effectiveness and safety of treatment with ketoconazole and itraconazole were compared in 773 sporotrichosis‐infected cats over a four‐year period (2002 to 2005). Five hundred and ninety‐eight cats received oral ketoconazole and 175 received oral itraconazole. Treatment was successful in 238 (30.8 per cent) cats, of which 171 (28.6 per cent) of 598 received 13.5 to 27.0 mg/kg/day ketoconazole and 67 (38.3 per cent) of 175 received 8.3 to 27.7 mg/kg/day itraconazole. Adverse effects were reported in 306 (39.6 per cent) of the cats, 105 (13.6 per cent) died and 430 (55.6 per cent) dropped out of treatment or were still under treatment at the time of data analysis.